NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $1.07 +0.01 (+0.94%) Closing price 04:00 PM EasternExtended Trading$1.07 0.00 (0.00%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncolytics Biotech Stock (NASDAQ:ONCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncolytics Biotech alerts:Sign Up Key Stats Today's Range$1.04▼$1.1550-Day Range$0.64▼$1.3252-Week Range$0.33▼$1.53Volume984,949 shsAverage Volume968,337 shsMarket Capitalization$107.39 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Read More Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreONCY MarketRank™: Oncolytics Biotech scored higher than 36% of companies evaluated by MarketBeat, and ranked 751st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOncolytics Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.28) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 26.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.51% of the float of Oncolytics Biotech has been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 0.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.51% of the float of Oncolytics Biotech has been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 0.41%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.81 News SentimentOncolytics Biotech has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Oncolytics Biotech this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCY Stock News HeadlinesCancer Treatment Revolution Drives $903B Market as New Therapies Gain MomentumAugust 28 at 10:39 AM | baystreet.caOncolytics Biotech® Announces Upcoming Investor Conferences in SeptemberAugust 28 at 8:30 AM | prnewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 28 at 2:00 AM | American Alternative (Ad)Here's Why We're Watching Oncolytics Biotech's (NASDAQ:ONCY) Cash Burn SituationAugust 27 at 8:57 AM | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 24, 2025 | americanbankingnews.comLake Street Initiates Coverage of Oncolytics Biotech (ONCY) with Buy RecommendationAugust 14, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of ShareholdersAugust 12, 2025 | finanznachrichten.deOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersAugust 11, 2025 | prnewswire.comSee More Headlines ONCY Stock Analysis - Frequently Asked Questions How have ONCY shares performed this year? Oncolytics Biotech's stock was trading at $0.9138 at the start of the year. Since then, ONCY shares have increased by 17.1% and is now trading at $1.07. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) posted its earnings results on Friday, August, 8th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.06. Who are Oncolytics Biotech's major shareholders? Oncolytics Biotech's top institutional shareholders include Seeds Investor LLC (0.23%). How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), QUALCOMM (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/08/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCY CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees30Year FoundedN/APrice Target and Rating Average Price Target for Oncolytics Biotech$5.00 High Price Target$7.00 Low Price Target$3.00 Potential Upside/Downside+371.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-438.11% Return on Assets-143.90% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book26.50Miscellaneous Outstanding Shares100,360,000Free Float100,261,000Market Cap$106.38 million OptionableNot Optionable Beta1.09 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ONCY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.